Translocations involving the immunoglobulin heavy chain locus (IGH@) are common abnormalities in lymphoma and mature B-lineage acute lymphoblastic leukaemia (ALL) 1 and more recently in B-cell precursor ALL (BCP-ALL). [2] [3] [4] In most cases, IGH@ translocations result in the transcriptional activation of an oncogene. 1 We report here a reciprocal translocation, t(14;19)(q32;p13), that juxtaposes the erythropoietin receptor precursor (EPOR) at 19p13 to the IGH@ enhancer resulting in its overexpression.
Cytogenetic analysis identified a reciprocal translocation between chromosomes 14 and 19, t(14;19)(q32;p13), in two patients with BCP-ALL who were registered on the Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute leukaemia 5 ( Figure 1a) . It was the sole chromosomal abnormality in patient no. 4860. In contrast, the karyotype of patient no. 10 672 showed two sidelines; one with the translocation, t(9;15)(q1?;q1?), and the other with a deletion of the short arm of chromosome 9 accompanying the t(14;19)(q32;p13). The two patients were different with respect to their clinical features (Table 1) . Patient no. 4860 received a bone marrow transplant (BMT) 5 months after diagnosis; he currently remains in complete remission 48 months after transplant. Patient no. 10 672 suffered a bone marrow relapse 6 months after diagnosis followed by BMT 4 months later. She remains alive at 13 months after diagnosis.
Cytogenetics and fluorescence in situ hybridization (FISH) were performed on the same fixed cells prepared from all samples. The involvement of IGH@ was determined by interphase FISH, using an IGH@ dual-colour break-apart rearrangement probe (Figure 1b) as described earlier.
2 This probe gave a positive result in both patients (Table 1 and Figure 1b ). All three remission samples for patient no. 10 672 had a normal signal pattern. In her relapse sample, the reappearance of the translocation was indicated by the presence of the same split signal pattern as seen at diagnosis in 62% of nuclei. FISH mapping of 19p in patient no. 10 672 identified EPOR as the IGH@ partner gene, confirmed by a home-grown dual-colour break-apart rearrangement probe in metaphase (Figures 1c and d) . A split signal pattern was observed in interphase nuclei from the diagnostic samples of both patients and the relapse sample of patient no. 10 672 (Table 1) , confirming the involvement of EPOR at both diagnosis and relapse.
Cloning by long-distance inverse PCR (LDI-PCR) (carried out as described earlier) 2 in patient no. 4860 identified the breakpoint on chromosome 14 to be within the IGHJ4 gene segment, whereas the breakpoint on 19p was located approximately 3 kb centromeric of EPOR at genomic location 11,359,017 (Figure 1d ). The different breakpoints within IGH@ in patient no. 10 672 could not be cloned using the LDI-PCR primers available. However, quantitative real-time PCR (qRT-PCR) studies were carried out on RNA samples from this patient. A greater than 230-fold increase in the expression of EPOR was observed in the diagnostic sample (Figure 1e ). Three , CISH (assay ID Hs_00367082) and PIM-1 (assay ID Hs_00171473). The endogenous control gene, B2M (assay ID Hs_99999907), was used to normalize the results of both patients and controls (Applied Biosystems, Foster City, California, USA). Expression levels were compared with the expression in four ALL patients without the translocation. Two patients with other IGH@ translocations, a patient with high hyperdiploidy, normal salivary gland and bone marrow (positive control for EPOR expression because of the presence of erythroid RNA, which is absent from patient samples from which the red blood cells have been removed as part of the preparation procedure) RNA (BD Biosciences, Oxford, UK) were used as controls.
Letters to the Editor additional samples (two remission and one relapse) were also available from patient no. 10 672 for expression analysis. The relapse sample showed high levels of EPOR expression (over 241-fold) similar to the diagnostic sample, whereas both remission samples showed a decrease in EPOR expression (down to 26-and 44-fold). Collectively, these data, along with the FISH results, provided evidence that this specific IGH@ translocation, t(14;19)(q32;p13), led to the EPOR overexpression seen in this patient.
EPOR belongs to the type 1 cytokine receptor family. Intracellular signalling from cytokine receptors is essential for the normal survival, proliferation and differentiation of haematopoietic cells, specifically the eythropoietic progenitor cells in the case of EPOR. 6 Recently, it has become apparent that EPOR also functions and is highly expressed in many normal and malignant tissues, highlighting its importance in cell survival. 6 EPOR is a homodimeric receptor and, upon binding to haematopoietic cells, it activates the Janus kinase 2 (JAK2)
der (14) der ( activating mutations. [7] [8] [9] Mutations in JAK2 are frequently observed in myeloproliferative disorders 10 and in Down's syndrome BCP-ALL (Malinge et al., 7 Ganmore et al. 11 and L Kearney, personal communication).
Material was available from patient no. 4860 to investigate whether the same JAK2 mutation within exon 14 as described in Down's syndrome BCP-ALL was present. No mutation was found and no suitable material was available to investigate patient no. 10 672. Thus, the activation of this pathway may be sustained by a mutation within a different exon of JAK2 or the presence of a different co-operating event.
Expression of BCL2L1, CISH and PIM-1, markers of STAT3/5 activation, were investigated in all samples from patient no. 10 672 (Figure 1e) . 12,13 mRNA levels of these target genes were increased, suggesting that this expression pattern was specific to t(14;19)(q32;p13), and that in patient no. 10672, the JAK-STAT pathway might be constitutively activated.
EPOR overexpression and the involvement of the PI3K/AKT pathway have been described in patients with ETV6-RUNX1-positive ALL. 14, 15 No material was available to assess the phosphorylation status of downstream targets in the two patients in this study; therefore, we were unable to confirm that high EPOR expression in association with the IGH@ translocation has the same downstream effects as those seen in ETV6-RUNX1-positive ALL patients.
We report here two BCP-ALL patients with a novel, recurrent, reciprocal translocation involving IGH@ and EPOR. EPOR mRNA expression was increased at diagnosis and relapse. The functional consequence of this translocation in lymphoid cells is currently unknown. Overexpressions of BCL2L1, CISH and PIM-1 suggest a potential block in apoptosis and increased proliferative advantage for these cells, the two main hallmarks of cancer.
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1 However, FISH is restricted, as information is available only for the genes/ loci for which probes are used. So, for a comprehensive genetic analysis, CC is essential because it provides an overview of all microscopically visible chromosome abnormalities important as prognostic factors.
Bacterial DNA and synthetic oligonucleotides containing a CpG motif (CpG-ODN) can activate cells of the immune system such as monocytes, dendritic cells and B cells.
2 Apart from stimulating cells, CpG-ODN have many direct effects on B-CLL cells, including upregulation of costimulatory molecules, cell cycle entry and upregulation of potential target antigens for antibody therapy. The use of the immunostimulatory CpGoligonucleotide DSP30 to effectively induce cell cycle progression of CLL cells in vitro has been reported. [3] [4] [5] [6] This proliferation is markedly enhanced upon the addition of interleukin-2 to cultures. 4, 7 Recently, Haferlach et al. 5 characterized 506 CLL stimulated with DSP30 þ IL-2. Metaphases were generated in 98.8% and aberrations detected in 83% of cases. Compared with FISH, chromosome analysis using CC resulted in the detection of additional abnormalities. The identification of subgroups with complex aberrant karyotypes suggested that CC might provide additional prognostic information.
To our knowledge and to date, there has been no direct comparison of classical TPA versus DSP30 þ IL-2. DSP30 þ IL-2 stimulation has been successfully tested in CLL but no data are available for other lymphoproliferations. We cultured 132 B-cell lymphoproliferations (80 CLL and 52 B-cell lymphoid neoplasms) in parallel, in the presence of TPA or DSP30 þ IL-2. The objective of this study was to evaluate the suitability of DSP30 þ IL-2 as a routine B-cell mitogen for metaphase cytogenetics.
In our cohort of 132 patients, diagnosed between December 2006 and October 2007, 76 patients were classified as CLL according to the World Health Organization Classification and the Matutes scoring system, 4 as atypical CLL, 10 as mantle cell lymphoma (3 in leukemic phase), 5 as follicular lymphoma (2 in leukemic phase), 4 as lymphoplasmacytic lymphoma (3 in leukemic phase), 4 as marginal zone B-cell lymphoma in leukemic phase, 1 as B-cell prolymphocytic leukemia, 1 as splenic lymphoma with villous lymphocytes, 1 as lymphocytosis with binucleated lymphocytes, 1 as hairy cell leukemia and 25 as small B-cell NHL (8 in leukemic phase and 1 in transformation) otherwise not categorized. Biological data are provided in Supplementary Table 1. Two cultures were carried out for each sample: one with DSP30 (1 mM) plus IL-2 (20 U/ml) and the other with TPA (50 mg/l). The number of metaphases per slide (assessed for an equal concentration of nuclei) was calculated with a metaphase finder (Metafer Msearch; Metasystems, Altlussheim, Germany) and the proportion of metaphases with clonal abnormalities was determined. Karyotypes with less than 20 normal metaphases were not retained (nos. 43 and 48). FISH was performed according to cytogenetics and morphology. Complete results of karyotypes with the two mitogenes and FISH are given in
